Advaxis to Host Investor & Analyst Day on June 12

PRINCETON, N.J.–(BUSINESS WIRE)– Advaxis,
Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing
cancer immunotherapies, today announced that it will host its annual Investor
& Analyst Day on Monday, June 12, at 1:00 p.m. in New York, NY.
The event will feature presentations followed immediately by a reception.

At this year’s Investor & Analyst Day, Advaxis will focus on “Patients,
Partnerships and Progress” with presentations centering around the
following areas:

• Clinical Trial Update with Case Study Highlights
• Plans for Data Dissemination and Timelines
• Update on Advaxis’ Corporate Collaborations
• Research Update on the NEO and HOT Programs
• Progress Towards Regulatory Submission and Commercial Readiness

During the Investor & Analyst Day, several investigators involved in
Advaxis’ ongoing clinical trials will highlight their experiences and
case studies in an interactive clinical symposium. An update will be
provided on the company’s global Phase 3 AIM2CERV study, as well as a
planned potentially registrational quality study of axalimogene
filolisbac for the treatment of metastatic cervical cancer. In addition,
the team will review the plans to file for marketing authorization for
axalimogene filolisbac in the European Union this year, an update on the
clinical collaboration with Amgen, Inc. on ADXS-NEO and more.

Attendance and Participation

To register for the event, please visit: www.advaxis.com.

About Advaxis, Inc.

Located in Princeton, N.J., Advaxis, Inc. is a late-stage biotechnology
company developing multiple cancer immunotherapies based on its
proprietary Lm Technology™. Lm Technology, using
bioengineered live attenuated Listeria monocytogenes (Lm)
bacteria, is the only known cancer immunotherapy agent shown in
preclinical studies to both generate cancer fighting T cells directed
against cancer antigens and neutralize Tregs and myeloid-derived
suppressor cells (MDSCs) that protect the tumor microenvironment from
immunologic attack and contribute to tumor growth. Advaxis’ lead Lm Technology
immunotherapy, axalimogene filolisbac, targets HPV-associated cancers
and currently has multiple clinical trials underway, including Phase 3
in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase
2 in anal cancer. The FDA has granted axalimogene filolisbac orphan drug
designation for each of these three clinical settings, as well as Fast
Track designation for adjuvant therapy for high-risk, locally advanced
cervical cancer (HRLACC) patients and a SPA for the Phase 3 AIM2CERV
trial in HRLACC patients. Axalimogene filolisbac has also been
classified as an advanced therapy medicinal product for the treatment of
cervical cancer by the European Medicines Agency’s Committee for
Advanced Therapies. Advaxis has two additional immunotherapy products:
ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid
tumors, in human clinical development. In addition, Advaxis and Amgen
are developing ADXS-NEO, an investigational cancer immunotherapy
treatment designed to activate a patient’s immune system to respond
against the unique mutations, or neoepitopes, contained in and
identified from each individual patient’s tumor, with plans to enter the
clinic in 2017.

To learn more about Advaxis, visit www.advaxis.com
and connect on Twitter,
LinkedIn,
Facebook,
and YouTube.

Advaxis Forward-Looking Statement

This press release contains forward-looking statements, including, but
not limited to, statements regarding Advaxis’ ability to develop the
next generation of cancer immunotherapies, and the safety and efficacy
of Advaxis’ proprietary immunotherapy, axalimogene filolisbac. These
forward-looking statements are subject to a number of risks including
the risk factors set forth from time to time in Advaxis’ SEC filings
including, but not limited to, its report on Form 10-K for the fiscal
year ended October 31, 2016, which is available at http://www.sec.gov.

Any forward-looking statements set forth in this presentation speak only
as of the date of this presentation. We do not intend to update any of
these forward-looking statements to reflect events or circumstances that
occur after the date hereof other than as required by law.

You are cautioned not to place undue reliance on any forward-looking
statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170518005590/en/